Researchers at the UK Dementia Research Institute in Edinburgh are using artificial intelligence to speed up drug discovery for neurological diseases by mining patient data—such as voice recordings and eye scans—and testing approved medicines on lab-grown brain cells. The approach aims to repurpose existing drugs, cutting timelines from decades to years, and is being funneled into multi-arm clinical trials like MND-SMART for motor neurone disease. Backers say AI-driven pattern recognition can flag compounds that shift diseased cellular signatures toward healthy ones, offering a cheaper, faster path than traditional R&D. The work arrives amid mixed results in Alzheimer’s therapeutics and parallel AI advances at U.S. labs, underscoring both promise and uncertainty. For patients like trial participant Steven Barrett, the platform approach offers hope even as the field navigates scientific and clinical setbacks.
Related articles:
HEALEY ALS Platform Trial
Highly accurate protein structure prediction with AlphaFold
